Edition:
United Kingdom

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

1.92USD
19 Oct 2018
Change (% chg)

-- (--)
Prev Close
$1.92
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
15,941
52-wk High
$5.49
52-wk Low
$1.70

Chart for

About

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal... (more)

Overall

Beta: -8.40
Market Cap(Mil.): $71.13
Shares Outstanding(Mil.): 0.12
Dividend: --
Yield (%): --

Financials

  AKTX.OQ Industry Sector
P/E (TTM): -- 85.41 33.64
EPS (TTM): -1.84 -- --
ROI: -68.01 0.21 14.27
ROE: -68.13 1.17 15.99

BRIEF-David Horn Solomon Resigns As CEO Of Akari Therapeutics

* AKARI THERAPEUTICS SAYS ON MAY 8, DAVID HORN SOLOMON, RESIGNED AS CEO AND AS A MEMBER OF BOARD EFFECTIVE IMMEDIATELY - SEC FILING

11 May 2018

Earnings vs. Estimates